先声药业周云曙:对外授权是阶段性选择,未来不再简单追求数量

第一财经
Sep 23

国产创新药出海BD(对外授权)交易火热,“卖青苗”争议随之而来,部分本土企业将早期管线海外权益提前授权给跨国药企,这种模式可以分担研发风险、验证中国创新价值,却也存在优质资产价值被低估的隐忧。  如何兼顾短期生存与长期产业收益,成为中国创新药企出海需要权衡的命题。  2026张江药谷大会暨上海国际生物医药产业周期间,先声药业总裁周云曙接受第一财经记者采访时表示,所谓“卖早了”“卖青苗”,与企业发展...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10